BeiGene Ltd. Sponsored ADR Stock

$191.32

0.14% day before yesterday

Nasdaq, Sep 06, 10:00 pm CET

ISIN

US07725L1026

Symbol

BGNE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

BeiGene Ltd. Sponsored ADR Stock price

$191.32

+70.71 58.63% 5Y

Nasdaq, Closing price Fri, Sep 06 2024

-0.26 0.14%

ISIN

US07725L1026

Symbol

BGNE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$18.59b
Enterprise Value	$17.06b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	5.51
P/S ratio (TTM) P/S ratio	6.00
P/B ratio (TTM) P/B ratio	6.03
Revenue growth (TTM) Revenue growth	71.01%
Revenue (TTM) Revenue	$3.10b
EBIT (operating result TTM) EBIT	$-886.27m
Free Cash Flow (TTM) Free Cash Flow	$-1.29b
Cash position	$2.62b
EPS (TTM) EPS	$-5.08
P/E forward	negative
P/S forward	5.15
EV/Sales forward	4.72
Short interest	3.89%

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

BeiGene Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

??

30 Analysts have issued a BeiGene Ltd. Sponsored ADR forecast:

28x Buy

93%

More details on Analyst Estimates Including Price Targets

30 Analysts have issued a BeiGene Ltd. Sponsored ADR forecast:

Buy

93%

Hold

Analyst Estimates with Stock Price Targets

Financial data from BeiGene Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '24		+/- %
Revenue	3,097 3,097	71% 71% 100%
- Direct Costs	556 556	44% 44% 18%
Gross Profit	2,540 2,540	78% 78% 82%
- Selling and Administrative Expenses	1,557 1,557	20% 20% 50%
- Research and Development Expense	1,774 1,774	8% 8% 57%
EBITDA	-791 -791	48% 48% -26%
- Depreciation and Amortization	96 96	25% 25% 3%
EBIT (Operating Income) EBIT	-886 -886	45% 45% -29%
Net Profit	-524 -524	70% 70% -17%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

BeiGene Ltd. Sponsored ADR Stock News

Neutral

Business Wire

●

13 days ago

BeiGene's BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/SLL

SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BGB-16673, an orally available investigational Bruton's tyrosine kinase (BTK) targeting chimeric degradation activation compound (CDAC), for adult patients ...

Positive

Seeking Alpha

●

16 days ago

BeiGene: Poised For Re-Rating As BTKi Sales Show Strong Beat

Zanubrutinib sales surprised the market, transforming from a follower to a market leader in BTK inhibitors. BeiGene turned profitable for the first time, alleviating concerns about funding needs. Expectations on BeiGene's pipeline were reset after setbacks, offering a favorable risk-reward opportunity.

Neutral

Business Wire

●

about one month ago

BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates

SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced results from the second quarter 2024 and corporate updates that strengthen the Company for future global growth. “This was a tremendous second quarter and an inflection point as BeiGene achieved positive non-GAAP operating income with rapidly ...

More BeiGene Ltd. Sponsored ADR News

Company Profile

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.

Head office	Cayman Islands
CEO	John Oyler
Employees	10,000
Founded	2010
Website	www.beigene.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now